@article{41d933aad01f41329e3a536ec2e0850f,
title = "Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence",
abstract = "The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of the KDIGO 2020 guideline on the topic. The guideline targets a broad audience of clinicians treating people with diabetes and CKD. Topic areas for which recommendations are updated based on new evidence include Chapter 1: Comprehensive care in patients with diabetes and CKD and Chapter 4: Glucose-lowering therapies in patients with type 2 diabetes (T2D) and CKD. The content of previous chapters on Glycemic monitoring and targets in patients with diabetes and CKD (Chapter 2), Lifestyle interventions in patients with diabetes and CKD (Chapter 3), and Approaches to management of patients with diabetes and CKD (Chapter 5) has been deemed current and was not changed. This guideline update was developed according to an explicit process of evidence review and appraisal. Treatment approaches and guideline recommendations are based on systematic reviews of relevant studies and appraisal of the quality of the evidence, and the strength of recommendations followed the “Grading of Recommendations Assessment, Development and Evaluation” (GRADE) approach. Limitations of the evidence are discussed, and areas for which additional research is needed are presented.",
keywords = "angiotensin II receptor blocker, angiotensin-converting enzyme inhibitor, chronic kidney disease, dialysis, evidence-based, GLP-1 receptor agonist, glycemia, glycemic monitoring, glycemic targets, guideline, HbA1c, hemodialysis, KDIGO, lifestyle, metformin, mineralocorticoid receptor antagonist, models of care, nutrition, renin–angiotensin system, self-management, SGLT2 inhibitor, systematic review, team-based care",
author = "Peter Rossing and Caramori, {M. Luiza} and Chan, {Juliana C.N.} and Heerspink, {Hiddo J.L.} and Clint Hurst and Kamlesh Khunti and Adrian Liew and Michos, {Erin D.} and Navaneethan, {Sankar D.} and Olowu, {Wasiu A.} and Tami Sadusky and Nikhil Tandon and Tuttle, {Katherine R.} and Christoph Wanner and Wilkens, {Katy G.} and Sophia Zoungas and Craig, {Jonathan C.} and Tunnicliffe, {David J.} and Tonelli, {Marcello A.} and Michael Cheung and Amy Earley and {de Boer}, {Ian H.}",
note = "Funding Information: PR reports consultancy fees from Astellas∗, AstraZeneca∗, Bayer Pharmaceuticals∗, Boehringer Ingelheim∗, Gilead∗, and Novo Nordisk∗; grant support from AstraZeneca∗ and Novo Nordisk∗; speaker fees from AstraZeneca∗, Boehringer Ingelheim∗, Eli Lilly and Company∗, and Novo Nordisk∗; educational presentations for Merck∗; and stock/stock options from Novo Nordisk. MLC reports consultancy fees from AstraZeneca, Bayer Pharmaceuticals, and Boehringer-Ingelheim; grant support from Bayer Pharmaceuticals∗, Boehringer-Ingelheim∗, and Novartis; and speaker fees from Bayer Pharmaceuticals. JCNC reports board membership with Asia Diabetes Foundation; consultancy fees from AstraZeneca∗, Bayer Pharmaceuticals∗, Boehringer Ingelheim∗, Celltrion, Merck Sharp & Dohme∗, Roche∗, Novartis∗, Sanofi∗, and Viatris∗; grant support from Applied Therapeutics∗, AstraZeneca∗, Eli Lilly and Company∗, Hua Medicine∗, Lee Powder∗, Merck∗, Pfizer∗, and Servier∗; speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim∗, Merck∗, Merck Sharp & Dohme∗, Sanofi∗, and Viatris∗; educational presentations for Boehringer Ingelheim∗; being founding director and shareholder of startup biogenetic testing company GEMVCARE, with partial support by the Hong Kong government; and being co-inventor for the patent of biomarkers for predicting diabetes and its complications. HJLH reports consultancy fees from Abbvie∗, AstraZeneca∗, Bayer Pharmaceuticals∗, Boehringer Ingelheim∗, CSL Behring ∗, Chinook∗, Dimerix, Gilead∗, Goldfinch Bio, Janssen∗, Merck & Co∗, Mundipharma, Mitsubishi Tanabe∗, Novo Nordisk∗, and Travere Pharmaceuticals∗; grant support from Abbvie∗, AstraZeneca∗, Boehringer Ingelheim∗, Janssen∗, and Novo Nordisk∗; and speaker fees from AstraZeneca and Bayer Pharmaceuticals. KK reports consultancy fees from Amgen, AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche, Sanofi, and Servier; speaker fees from Amgen, AstraZeneca, Bayer Pharmaceuticals, Berlin-Chemie AG/Menarini Group, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Merck Sharp & Dohme, Napp, Novartis, Novo Nordisk, Roche, and Sanofi; grant support from AstraZeneca∗, Boehringer Ingelheim∗, Eli Lilly and Company∗, Janssen∗, Merck Sharp & Dohme∗, Novartis∗, Novo Nordisk∗, Roche∗, and Sanofi∗; and general support from National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM), and NIHR Leicester Biomedical Research Centre (BRC). AL reports consultancy fees from Alnylam Pharmaceuticals, AstraZeneca, Baxter Healthcare, Bayer Pharmaceuticals, Boehringer Ingelheim, Chinook Therapeutics, DaVita Inc, Eledon, George Clinical, Otsuka Pharmaceuticals, and ProKidney; and speaker fees from Baxter Healthcare, Chinook Therapeutics, DKSH Singapore, and Otsuka Pharmaceuticals. EDM reports consultancy fees from AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim, Esperion, Novartis, Novo Nordisk, and Pfizer. SDN reports consultancy fees from AstraZeneca, ACI Clinical, Bayer Pharmaceuticals, Boehringer Ingelheim/Lilly, Vertex, and Vifor. NT reports grant support from the Government of India; the Indian Council of Medical Research; the National Heart, Lung, and Blood Institute/National Institutes of Health; and Novo Nordisk. KRT reports consultancy fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Gilead, Goldfinch Bio, Novo Nordisk, and Travere; grant support from Bayer Pharmaceuticals∗, Goldfinch Bio∗, Novo Nordisk∗, and Travere; and speaker fees from AstraZeneca, Eli Lilly and Company, Gilead, Goldfinch Bio, Janssen, and Novo Nordisk. CW reports being a board member for Bayer Pharmaceuticals, Boehringer Ingelheim, Genzyme-Sanofi, Gilead, GSK, Idorsia, Merck Sharp & Dohme, and Tricida; consultancy fees from Akebia, Amicus, Chiesi, and Vifor Fresenius Medical Care Renal Pharma; and speaker fees from Amgen, Amicus, AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim, Eli Lilly and Company, Fresenius Medical Care, Genzyme-Sanofi, Merck Sharp & Dohme, Novartis, and Takeda. SZ reports being an advisory board member for AstraZeneca∗, Boehringer Ingelheim∗, Merck Sharp & Dohme Australia∗, Novo Nordisk∗, and Sanofi∗; speaker fees from Servier Laboratories Australia∗; and being an expert committee member for Eli Lilly and Company∗. MAT reports speaker fees from AstraZeneca. IHdB reports consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Cyclerion Therapeutics, George Clinical, Goldfinch Bio, Lilly, Medscape, and Otsuka/Ironwood; and grant support from Dexcom∗, JDRF∗, and Novo Nordisk∗. All the other authors declared no competing interests. Funding Information: A special debt of gratitude is owed to the following people for their contribution to this important guideline effort: Melissa Thompson, Debbie Maizels, Patrizia Natale, Giovanni F.M. Strippoli, Gail Y. Higgins, Tess E. Cooper, Narelle S. Willis, Michel Jadoul, Wolfgang C. Winkelmayer, Kathleen Conn, Danielle Green, Tanya Green, Coral Cyzewski, and John Davis. The development and publication of this guideline were supported by KDIGO. The opinions or views expressed in this summary are those of the authors and do not necessarily reflect the opinions or recommendations of the International Society of Nephrology or Elsevier. Dosages, indications, and methods of use for products that are referred to by the authors may reflect their clinical experience or may be derived from the professional literature or other clinical sources. Publisher Copyright: {\textcopyright} 2022 International Society of Nephrology",
year = "2022",
month = nov,
doi = "10.1016/j.kint.2022.06.013",
language = "English",
volume = "102",
pages = "990--999",
journal = "Kidney International",
issn = "0085-2538",
publisher = "ELSEVIER SCIENCE INC",
number = "5",
}